IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee. (IMPACT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02037204 |
Recruitment Status :
Completed
First Posted : January 15, 2014
Results First Posted : January 1, 2019
Last Update Posted : January 1, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Foreign-Body Reaction Inflammation Effusion (L) Knee Knee Pain Swelling | Other: Cartilage repair surgery | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 35 participants |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | First in man surgery: autologous chondrons are mixed with allogeneic MSCs and implanted in a fibrin glue carrier in a one-stage surgical procedure. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Instant MSC Product Accompanying Autologous Chondron Transplantation (IMPACT): Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee. |
Study Start Date : | March 2013 |
Actual Primary Completion Date : | April 2016 |
Actual Study Completion Date : | April 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: Cartilage repair surgery
Single-stage cartilage repair surgery using autologous chondrons (10-20%) and allogeneic MSCs (80-90%) in a fibrin glue carrier with a dosage of two million cells/ cm2 applied once during a surgical procedure.
|
Other: Cartilage repair surgery
Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs
Other Names:
|
- Safety: Adverse Events [ Time Frame: 18 months ]Adverse events rate
- Clinical Improvement, Knee Injury and Osteoarthritis Outcome Score [ Time Frame: 3 and 18 months ]Clinical improvement as measured by patient reported outcome scores. The questionnaire has been developed to evaluate the symptoms and limitations for patients with osteoarthritis. The outcome of the KOOS-scale varies from 0-100, where 0 indicates the greatest possible problems and is the worst outcome and 100 indicates no problems.
- Structural Repair [ Time Frame: 12 months ]To examine parameters of structural repair at one year after treatment using MRI and a second-look arthroscopy.
- Health Care Use and Costs [ Time Frame: 18 months ]To assess the healthcare use and costs related to the procedure as well as the health-related work leave during the study period.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age >18 and <45 years old
- Symptomatic isolated full-thickness articular cartilage lesion on the femoral condyle or trochlea.
- Size 2 - 8 cm2
- Intact anterior cruciate ligament
Exclusion Criteria:
- (History of) osteoarthritis, defined as Kellgren-Lawrence grade >3 as determined from appropriate X-ray.
- Concomitant inflammatory disease that affects the joint (rheumatoid arthritis, metabolic bone disease, psoriasis, gout, symptomatic chondrocalcinosis)
- (History of) Septic arthritis.
- Malalignment requiring an osteotomy.
- (History of) total menisectomy in the target knee joint.
- Any surgery in the knee joint 6 months prior to study inclusion.
- Risk groups for MRI scanning due to the magnetic field like patients with pacemakers, nerve stimulators, metal particles, stents, clips or implants, (possible) pregnancy or breast feeding.
- Patients with severe anxiety for MRI scans and/or needles

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02037204
Netherlands | |
University Medical Center Utrecht | |
Utrecht, Netherlands, 3508GA |
Study Director: | Tommy S. de Windt, MD | UMC Utrecht | |
Principal Investigator: | Daniel B.F. Saris, MD, PhD | UMC Utrecht |
Additional Information:
Publications:
Responsible Party: | D.B.F. Saris, MD, PhD, Orthopaedic surgeon, UMC Utrecht |
ClinicalTrials.gov Identifier: | NCT02037204 History of Changes |
Other Study ID Numbers: |
IMPACT |
First Posted: | January 15, 2014 Key Record Dates |
Results First Posted: | January 1, 2019 |
Last Update Posted: | January 1, 2019 |
Last Verified: | June 2018 |
IMPACT Chondrons Mesenchymal stem cells Allogeneic MSCs |
single-stage Cartilage repair Safety Efficacy |
Inflammation Foreign-Body Reaction Foreign Bodies Pathologic Processes Wounds and Injuries |